Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M, Merino, Maria J, Swisher, Elizabeth M, Harrell, Maria I, Trepel, Jane B, Lee, Min-Jung, Bagheri, MohammaLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30009-3
Date:
January, 2018
File:
PDF, 432 KB
english, 2018